|
|
|
|
With over 7,000 rare diseases, most of which are genetically linked, the potential for nanomedicine to revolutionize treatment is immense. While polymer nanoparticles offer unique advantages, like the ability to engineer specific attributes, several challenges remain.
|
|
|
|
|
When applied to the manufacturing of emerging genetic medicines, the “scale-out” approach is poised to revolutionize production by enhancing speed, safety, and regulatory efficiency while reducing costs and expanding patient access to critical treatments.
|
|
|
|
|
As demand grows for faster development timelines and more resilient supply chains, manufacturers must embrace a more agile approach. Battelle helped a specialty pharma company pioneer in-package 3D printing to manufacture customized tablets directly into blister packaging.
|
|
|
|
|
Autoinjectors have transformed how we deliver—and think about—injectable drugs, but advances in drug formulation, alternative delivery platforms, environmental considerations, and patient expectations are all reshaping the landscape and raising new questions.
|
|
|
|
|
Microphysiological systems (MPS) have generated tremendous excitement over the past decade as a more human-relevant alternative to animal models. The question now: how far can they go in transforming drug discovery, safety testing and, ultimately, patient care?
|
|
|
